Abstract
Background
Calciphylaxis in end-stage renal disease is characterized by painful necrotic skin ulcers and high mortality. There are no approved therapies. SNF472, an intravenous formulation of myo-inositol hexaphosphate, inhibits the formation and growth of hydroxyapatite crystals, the final common pathway in the pathogenesis of vascular calcification.
Methods
In this open-label, single-arm study, calciphylaxis patients on thrice-weekly hemodialysis and standard care, received intravenous SNF472 3 times per week for 12 weeks. The primary endpoint was wound healing assessed using the quantitative Bates-Jensen Wound Assessment Tool (BWAT). Pain visual analog scale (VAS), quality of life (wound-QoL), and qualitative wound image review were secondary endpoints. Quantitative changes from baseline were analyzed by paired t-tests using multiple imputation to account for missing observations.
Results
Fourteen patients received SNF472. Improvements from baseline to week 12 were observed for mean BWAT score (− 8.1; P < 0.001), pain VAS (− 23.6 mm; P = 0.015) and wound-QoL global score (− 0.90; P = 0.003). Of the 9 patients with ulcerated lesions at baseline who completed treatment, wound image review showed improvement for 7. SNF472 was well tolerated with no serious treatment-related adverse events. The most common adverse events were infections which occur frequently in patients on hemodialysis. None of these were considered as treatment-related.
Conclusions
SNF472 was well-tolerated and improvements from baseline to week 12 in wound healing, pain, and quality of life were observed. A randomized, double-blind, placebo-controlled trial is planned to evaluate SNF472 in patients with calciphylaxis.
Similar content being viewed by others
References
Goel SK, Bellovich K, McCullough PA (2011) Treatment of severe metastatic calcification and calciphylaxis in dialysis patients. Int J Nephrol 2011:701603. https://doi.org/10.4061/2011/701603
Nunley JR (2017) Calciphylaxis. https://emedicine.medscape.com/article/1095481-overview. Accessed 1 June 2019
Schlieper G, Brandenburg V, Ketteler M, Floege J (2009) Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol 5:539–543. https://doi.org/10.1038/nrneph.2009.99
Oliveira TM, Frazao JM (2015) Calciphylaxis: from the disease to the diseased. J Nephrol 28:531–540. https://doi.org/10.1007/s40620-015-0192-2
Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089. https://doi.org/10.1016/S0039-6060(97)90212-9 (discussion 1089–1090)
Budisavljevic MN, Cheek D, Ploth DW (1996) Calciphylaxis in chronic renal failure. J Am Soc Nephrol 7:978–982
Nigwekar SU, Thadhani R, Brandenburg VM (2018) Calciphylaxis. N Engl J Med 378:1704–1714. https://doi.org/10.1056/NEJMra1505292
Brandenburg VM, Kramann R, Rothe H, Kaesler N, Korbiel J, Specht P, Schmitz S, Krüger T, Floege J, Ketteler M (2017) Calcific uraemic arteriolopathy (calciphylaxis): data from a large nationwide registry. Nephrol Dial Transplant 32:126–132. https://doi.org/10.1093/ndt/gfv438
Sanguankeo A, Thamcharoen N, Upala S (2017) Calciphylaxis in a nondialysis patient treated with sodium thiosulfate and high dose of oxygen. Clin Nephrol Case Stud 5:38–41
Mochel MC, Arakaki RY, Wang G, Kroshinsky D, Hoang MP (2013) Cutaneous calciphylaxis: a retrospective histopathologic evaluation. Am J Dermatopathol 35:582–586. https://doi.org/10.1097/DAD.0b013e31827c7f5d
Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI (2015) Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis 66:133–146. https://doi.org/10.1053/j.ajkd.2015.01.034
Hafner J, Keusch G, Wahl C, Sauter B, Hurlimann A, von Weizsacker F, Krayenbuhl M, Biedermann K, Brunner U, Helfenstein U (1995) Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy. J Am Acad Dermatol 33:954–962
Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217. https://doi.org/10.1046/j.1523-1755.2002.00375.x
Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579. https://doi.org/10.1016/j.jaad.2006.08.065
Auriemma M, Carbone A, Di Liberato L, Cupaiolo A, Caponio C, De Simone C, Tulli A, Bonomini M, Amerio P (2011) Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature. Am J Clin Dermatol 12:339–346. https://doi.org/10.2165/11587060-000000000-00000
Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr (2013) Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 8:1162–1170. https://doi.org/10.2215/CJN.09880912
Peng T, Zhuo L, Wang Y, Jun M, Li G, Wang L, Hong D (2018) Systematic review of sodium thiosulfate in treating calciphylaxis in chronic kidney disease patients. Nephrology (Carlton) 23:669–675. https://doi.org/10.1111/nep.13081
Ferrer MD, Ketteler M, Tur F, Tur E, Isern B, Salcedo C, Joubert PH, Behets GJ, Neven E, D’Haese PC, Perello J (2018) Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification. PLoS ONE 13:e0197061. https://doi.org/10.1371/journal.pone.0197061
Ferrer MD, Perez MM, Canaves MM, Buades JM, Salcedo C, Perello J (2017) A novel pharmacodynamic assay to evaluate the effects of crystallization inhibitors on calcium phosphate crystallization in human plasma. Sci Rep 7:6858. https://doi.org/10.1038/s41598-017-07203-x
Perelló J, Gómez M, Ferrer MD, Rodríguez NY, Salcedo C, Buades JM, Pérez MM, Torregrosa JV, Martín E, Maduell F (2018) SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. J Nephrol 31:287–296. https://doi.org/10.1007/s40620-018-0471-9
Perelló J, Joubert PH, Ferrer MD, Canals AZ, Sinha S, Salcedo C (2018) First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. Br J Clin Pharmacol 84:2867–2876. https://doi.org/10.1111/bcp.13752
Bates-Jensen BM, Vredevoe DL, Brecht ML (1992) Validity and reliability of the pressure sore status tool. Decubitus 5:20–28
Augustin M, Baade K, Heyer K, Price PE, Herberger K, Wild T, Engelhardt M, Debus ES (2017) Quality-of-life evaluation in chronic wounds: comparative analysis of three disease-specific questionnaires. Int Wound J 14:1299–1304. https://doi.org/10.1111/iwj.12803
Olsen MF, Bjerre E, Hansen MD, Tendal B, Hilden J, Hróbjartsson A (2018) Minimum clinically important differences in chronic pain vary considerably by baseline pain and methodological factors: systematic review of empirical studies. J Clin Epidemiol 101:87–106.e2. https://doi.org/10.1016/j.jclinepi.2018.05.007
Olsen MF, Bjerre E, Hansen MD, Hilden J, Landler NE, Tendal B, Hróbjartsson A (2017) Pain relief that matters to patients: systematic review of empirical studies assessing the minimum clinically important difference in acute pain. BMC Med 15:35. https://doi.org/10.1186/s12916-016-0775-3
Torregrosa JV, Ramos AM (2010) Use of bisphosphonates in chronic kidney disease. Nefrologia 30:288–296
Torregrosa JV, Duran CE, Barros X, Blasco M, Arias M, Cases A, Campistol JM (2012) Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia 32:329–334
Jeong HS, Dominguez AR (2016) Calciphylaxis: controversies in pathogenesis, diagnosis and treatment. Am J Med Sci 351:217–227. https://doi.org/10.1016/j.amjms.2015.11.015
Riemer CA, El-Azhary RA, Wu KL, Strand JJ, Lehman JS (2017) Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review. Br J Dermatol 177:1510–1518. https://doi.org/10.1111/bjd.15702
Hayden MR, Goldsmith DJ (2010) Sodium thiosulfate: new hope for the treatment of calciphylaxis. Semin Dial 23:258–262. https://doi.org/10.1111/j.1525-139X.2010.00738.x
Yu Z, Gu L, Pang H, Fang Y, Yan H, Fang W (2015) Sodium thiosulfate: an emerging treatment for calciphylaxis in dialysis patients. Case Rep Nephrol Dial 5:77–82. https://doi.org/10.1159/000380945
Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS (2015) The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J Am Soc Nephrol 10:800–807. https://doi.org/10.2215/CJN.10221014
Russo D, Capuano A, Cozzolino M, Napolitano P, Mosella F, Russo L, Saviano C, Zoccali C (2016) Multimodal treatment of calcific uraemic arteriolopathy (calciphylaxis): a case series. Clin Kidney J 9:108–112. https://doi.org/10.1093/ckj/sfv120
Acknowledgements
The study was supported by Laboratoris Sanifit. Medical writing support from Jonathan Latham of PharmaScribe, LLC was funded by Sanifit. The study was conducted in the US at Frenova Renal Research® and Davita Kidney Care sites, and in the UK at the Salford Royal NHS Foundation Trust. Sanifit thanks Dr. Barbara Bates-Jensen for permission to use the BWAT in this study.
Author information
Authors and Affiliations
Contributions
VB, SS, JT, AZC, PJ, CS, and JP contributed to the study concept and design. VB and SS contributed to the acquisition of data. VB, SS, RG, SM, AZC, CS, KJC, AG, and JP contributed to the conduct, analysis and interpretation of the data. SM and RG drafted the article. All authors contributed to critical editing and revising the article for important intellectual content. All authors provided final approval of the version to be published. All authors agree to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Conflict of interest
VB is a consultant to Pharmacosmos, Vifor, and FMC, received lecture fees from Amgen, Pfizer, Bayer, Pharmacosmos, Vifor, FMC, Servier, Novartis, Daiichi-Sankyo, and Cardiobridge, received a grant for the European Calciphylaxis Network EuCalNet from Amgen, and received grants from Pfizer, Bayer, Sanifit, Pharmacosmos, Vifor, FMC, Servier, Novartis, Daiichi-Sankyo, and Cardiobridge. SS is a consultant to Sanifit, and received lecture fees from Vifor Fresenius, MSD, and Boehringer Ingelheim. JT has no conflicts to disclose. KJC and PJ, are consultants to Sanifit. RG, SM and AG are employees and shareholders of Sanifit Therapeutics. AZC is an employee and shareholders of Sanifit and has a patent pending related to SNF472. CS is an employee of Sanifit and has patents related to SNF472. JP is an employee and shareholder of Sanifit, and has patents owned or controlled by Sanifit.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Patients gave written informed consent to participate.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Brandenburg, V.M., Sinha, S., Torregrosa, JV. et al. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. J Nephrol 32, 811–821 (2019). https://doi.org/10.1007/s40620-019-00631-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-019-00631-0